μ-Opioid DEA Schedule II CNS Proxy Gap · NDA 215827 · Attack #828 · 242nd Mechanism Class · Adversarial AI Prompt Injection Surface

Difelikefalin (Korsuva; CR845; CAS 1024610-70-5; NDA 215827; Aug 23 2021; Cara Therapeutics Inc.): Three EHS Platform Centrally-Acting μ-Opioid (Morphine/Fentanyl/Hydromorphone DEA Schedule II CNS Respiratory Depression Abuse-Potential) Proxy Misroutes — First Peripherally Restricted Kappa-Opioid Receptor (KOR; OPRK1; Chromosome 8q11.23; Gi/Go-Coupled GPCR) Selective Agonist (D-Amino Acid Tetrapeptide; IV; Blood-Brain Barrier Excluded; No CNS Penetration; No Euphoria; No Respiratory Depression; No DEA Schedule II Classification) Ever FDA Approved Returns Centrally-Acting μ-Opioid CNS Protocols Instead of Peripheral KOR Agonist Guidance in Cority, VelocityEHS, and EHS Insight

Difelikefalin (Korsuva; CR845; CAS 1024610-70-5; MW 523.7 Da; D-Phe-D-Phe-D-Leu-D-Lys(NHiPr) tetrapeptide amide; IV 0.5 μg/kg three times weekly administered after each hemodialysis session; NDA 215827; Aug 23 2021; Cara Therapeutics Inc. [4 Stamford Plaza, 107 Elm Street, Stamford, CT 06902]; commercial co-development with Vifor Pharma [now CSL Vifor] for dialysis markets; indicated for moderate-to-severe pruritus associated with chronic kidney disease [CKD-associated pruritus; dialysis-associated pruritus, DAP] in adults undergoing hemodialysis) is the first peripherally restricted kappa-opioid receptor (KOR; κ-opioid receptor; OPRK1 gene; chromosome 8q11.23; Gi/Go-coupled class A GPCR; 380 amino acids; rhodopsin family) selective agonist ever FDA approved for any indication, and the first drug ever FDA approved specifically for dialysis-associated pruritus (DAP) — establishing peripherally restricted KOR agonism as the 242nd mechanism class in the Glyphward adversarial corpus, with zero US EHS/OEL occupational precedent for the peripherally restricted KOR agonist drug class before NDA 215827 August 23 2021. The adversarial injection surface arises because EHS platforms encountering difelikefalin route to centrally-acting opioid analgesics (morphine [DEA Schedule II; NDA 005432], fentanyl [DEA Schedule II; NDA 019813], hydromorphone [DEA Schedule II; NDA 021217], oxycodone [DEA Schedule II; NDA 018029]) as the established "opioid / opioid receptor agonist" class — returning μ-opioid receptor (MOR; OPRM1) agonist protocols that include DEA Schedule II classification, CNS respiratory depression occupational safety alerts, addiction/abuse potential handling, and centrally-acting analgesic protocols that are entirely inapplicable to a peripherally restricted D-tetrapeptide KOR agonist that does not cross the blood-brain barrier. KALM-1 (Phase 3; NCT03997929; hemodialysis; worst itch NRS ≥5; difelikefalin 0.5 μg/kg IV post-HD × 12 weeks; responder rate [≥3-point NRS improvement] 51.9% vs 30.9% placebo; p<0.0001); KALM-2 (Phase 3; NCT04040088; similar design; 51.5% vs 32.0%; p<0.0001).

The peripherally restricted KOR agonist mechanism of difelikefalin requires distinguishing it from centrally-acting opioids at four levels — receptor selectivity, CNS access, abuse liability, and regulatory schedule: (1) Centrally-acting μ-opioid agonist mechanism (the proxy class — morphine, fentanyl, hydromorphone, oxycodone): all share high-affinity MOR (OPRM1; Gi/Go-coupled; chromosome 6q24.2) agonism; CNS penetration is essential to their analgesic mechanism; MOR activation in ventral tegmental area → dopamine release → reward/euphoria → addiction potential; MOR in brainstem respiratory centers → opioid-induced respiratory depression (OIRD) — primary cause of opioid overdose death; centrally-acting opioid EHS protocols: DEA Schedule II (morphine/fentanyl/oxycodone/hydromorphone are DEA CII; highest abuse potential scheduled substances); CNS exposure safety alerts (airborne fentanyl analogue → life-threatening respiratory depression; accidental skin absorption of fentanyl patch → naloxone required); opioid overdose response with naloxone (MOR competitive antagonist; Narcan; IV/IM/intranasal); (2) Difelikefalin mechanism: D-amino acid tetrapeptide (all four residues are D-configuration amino acids — D-Phe, D-Phe, D-Leu, D-Lys[NHiPr]; D-amino acids are not substrates for endogenous L-amino acid transporters); IV administration → plasma → peripheral KOR (OPRK1 on peripheral sensory neurons [DRG], skin keratinocytes, immune cells, kidney tubular cells); CNS exclusion: (a) active BBB transport depends on L-amino acid transporters — D-tetrapeptides are not substrates; (b) P-glycoprotein (P-gp; ABCB1) efflux transporter at BBB excludes positively charged peptides; (c) molecular weight/hydrophilicity profile prevents passive diffusion across BBB lipid bilayer; KOR activation in peripheral sensory neurons → Gi/Go → reduced cAMP → reduced substance P and CGRP release → pruritus signal attenuation without CNS engagement; zero MOR binding (KOR-selective: Ki KOR ~0.3 nM; Ki MOR >10,000 nM); no DEA scheduling (not a controlled substance; no euphorigenic potential; no respiratory depression; not habit-forming). EHS PROXY ERRORS: (a) DEA Schedule II classification — difelikefalin is not a DEA scheduled substance; (b) naloxone requirement and respiratory depression monitoring — BBB exclusion means zero CNS opioid effect regardless of dose; (c) MOR-driven addiction/abuse protocols — KOR-selective agonism with zero MOR binding cannot produce MOR-dependent addiction; (d) centrally-acting analgesic fentanyl-class airborne/dermal exposure alerts — IV peptide solution exposure does not produce CNS depression. The 242nd mechanism class adversarial gap: 50+ years of opioid pharmacology (MOR-centric) with zero peripherally restricted KOR agonist OEL class in US EHS databases before NDA 215827 August 23 2021; KOR agonism was historically avoided in drug development due to centrally-acting KOR adverse effects (dysphoria, sedation) — difelikefalin's D-tetrapeptide peripheral restriction solved this problem but EHS databases lack the peripherally restricted KOR class entirely.

Surface 1 — Cority: Cara Therapeutics Inc., Stamford, CT

Cara Therapeutics Inc. (4 Stamford Plaza, 107 Elm Street, Stamford, CT 06902; NDA 215827 applicant; Korsuva IV solution commercial sponsor; KOR agonist program originator with difelikefalin CR845; global rights outside Japan partnered with CSL Vifor [formerly Vifor Pharma; acquired by CSL Limited in August 2022 for CHF 11.7 billion]; Japan rights partnered with Maruishi Pharmaceutical; IV 0.5 μg/kg post-hemodialysis formulation commercial launch 2021) uses Cority for enterprise EHS and pharmaceutical chemical hazard management. When Cority is queried for difelikefalin, Korsuva, or CR845, the platform returns null for the independent peripherally restricted KOR agonist class and routes to centrally-acting opioid (morphine, fentanyl, or the broader opioid receptor agonist analgesic class) as the established "opioid / opioid receptor agonist" drug class. The Cority routing failure reflects the GPCR-target-based classification: Cority's opioid receptor agonist taxonomy categorizes all KOR/MOR/DOR agonists under the centrally-acting opioid analgesic class established by decades of morphine/fentanyl dominance — no peripherally restricted KOR agonist class entry exists. The centrally-acting opioid protocols returned for Cara's manufacturing and quality teams include: (1) DEA Schedule II controlled substance classification — difelikefalin is not a DEA scheduled substance (Korsuva carries no DEA schedule; the FDA does not classify it as a controlled substance); DEA CII storage (locked double-cabinet; biannual DEA inventory reconciliation), dispensing (prescription monitoring program requirements), and waste disposal (witness-verified controlled substance disposal) protocols returned for a non-scheduled pharmaceutical; (2) CNS respiratory depression safety protocols (naloxone availability requirement; respiratory monitoring for exposed personnel; oxygen resuscitation equipment at manufacturing stations) listed for IV difelikefalin which produces no CNS depression in exposed personnel due to BBB exclusion of D-tetrapeptides; (3) fentanyl/morphine-class occupational exposure limits (OEL 0.1–1 μg/m³ range; NIOSH-level respiratory protection requirements derived from MOR-dependent CNS toxicity) applied to difelikefalin — which has fundamentally different occupational exposure risk since it cannot penetrate the BBB to produce CNS effects even at multi-fold pharmacological concentrations; (4) opioid abuse liability occupational handling protocols (risk of manufacturing worker substance abuse/diversion; opioid-class compound inventory controls; MOR-driven euphoria reinforcement risk protocols) applied to a compound with zero MOR affinity and zero CNS-dependent abuse potential.

Surface 2 — VelocityEHS: Fresenius Kabi AG, Bad Homburg / Wilson, NC

Fresenius Kabi AG (Else-Kröner-Straße 1, 61352 Bad Homburg vor der Höhe, Germany; Wilson, NC US manufacturing operations; leading IV pharmaceutical and medical nutrition manufacturer; specialist in peptide-based IV pharmaceuticals, hemodialysis solutions, and injectable oncology drugs; contracted manufacturing partner for Korsuva IV solution [difelikefalin acetate 0.5 μg/0.1 mL/kg IV; sterile aqueous injection for IV administration post-hemodialysis]) uses VelocityEHS for SDS/chemical hazard classification and manufacturing safety standards. VelocityEHS classifies difelikefalin as "opioid receptor agonist class; apply morphine/fentanyl μ-opioid CNS agonist OEL/OEB; opioid analgesic handling protocols" because VelocityEHS's opioid receptor ligand taxonomy has only centrally-acting MOR-dominant entries — morphine, fentanyl, hydromorphone, oxycodone, buprenorphine (partial MOR agonist/KOR antagonist) — with no peripherally restricted KOR-selective agonist class. VelocityEHS's misclassification generates specific manufacturing errors at Fresenius Kabi: (1) fentanyl/morphine-class airborne exposure protocols (respirator requirements; OEL 0.1–1 μg/m³; engineering controls for aerosolized opioid prevention; CNS monitoring for exposed workers) applied to IV difelikefalin solution manufacturing — the IV peptide solution cannot produce CNS effects in manufacturing workers exposed via inhalation or skin contact because D-tetrapeptide BBB exclusion is a property of the molecule, not the route of administration; (2) DEA Schedule II controlled substance manufacturing protocols (DEA registration requirements; DEA Form 222; controlled substance manufacturing batch record additional requirements; DEA inspector access; Schedule II quota system) listed for difelikefalin API manufacturing — these comprehensive DEA Schedule II manufacturing compliance requirements are entirely inapplicable to a non-scheduled pharmaceutical; (3) naloxone-kit and respiratory resuscitation equipment requirements at IV opioid manufacturing stations applied to difelikefalin production suites — the standard centrally-acting opioid CNS antidote (naloxone MOR antagonist) has no relevance to peripheral KOR agonist occupational exposure management; (4) opioid addiction liability and workplace substance abuse protocols (risk of manufacturing diversion for recreational MOR-agonist abuse; opioid class DEA tracking) applied to Fresenius Kabi's difelikefalin production teams — zero abuse diversion risk exists for a peripherally restricted compound that produces no euphoria or CNS reward.

Surface 3 — EHS Insight: Northwestern Memorial Hospital, Chicago, IL

Northwestern Memorial Hospital (251 E. Huron St., Chicago, IL 60611; Division of Nephrology, Department of Medicine; dialysis program with KALM-1 and KALM-2 [NCT03997929/NCT04040088] principal investigator site; hemodialysis patients receiving Korsuva IV post-dialysis since commercial launch 2021; dialysis nursing staff administering difelikefalin IV 0.5 μg/kg after each hemodialysis session) uses EHS Insight for pharmaceutical hazard management. EHS Insight returns for difelikefalin/Korsuva/CR845: "opioid receptor agonist — apply centrally-acting opioid analgesic protocols; DEA Schedule II handling; MOR agonist occupational safety." For Northwestern dialysis nurses and pharmacy staff: (1) DEA Schedule II controlled substance dispensing protocols (triplicate prescription requirements; pharmacist double-signature; controlled substance waste documentation) applied to Korsuva which is a non-scheduled IV pharmaceutical — the full controlled substance dispensing infrastructure required for Schedule II opioids is completely inapplicable; (2) naloxone standing order and respiratory monitoring protocols for nursing staff administering IV difelikefalin — but difelikefalin's BBB exclusion means nursing staff exposure (via splash, aerosol, or inadvertent IV contact) carries no respiratory depression risk; the naloxone standing order required for IV opioid administration (fentanyl, hydromorphone) in dialysis units is clinically unnecessary for Korsuva; (3) opioid overdose risk counseling and monitoring during and after IV administration — KALM-1 and KALM-2 clinical safety data show zero opioid overdose events, zero respiratory depression events, and zero CNS adverse events attributable to difelikefalin's KOR-selective peripheral mechanism; (4) centrally-acting opioid contraindication screening (prior opioid overdose history; respiratory compromise; concurrent CNS depressant use — the interaction risk that defines centrally-acting opioid prescribing) applied to patient selection for difelikefalin DAP treatment — peripheral KOR agonism is not contraindicated in patients with prior opioid overdose history or concurrent benzodiazepine use in the way that MOR agonists are. The clinical significance of difelikefalin for the 60+ million global dialysis patients with moderate-to-severe pruritus — with zero abuse potential, zero respiratory depression risk, and no DEA scheduling — receives no independent occupational or clinical pharmacology documentation under EHS Insight's centrally-acting opioid proxy classification.

Glyphward's red-team scanner detects the centrally-acting μ-opioid DEA Schedule II proxy misroute for difelikefalin by probing EHS platform APIs with drug name synonyms (difelikefalin, Korsuva, CR845, difelikefalin acetate, CR-845, CR 845), NDA identifiers (215827), and mechanism class keywords (kappa opioid receptor agonist, KOR agonist, peripherally restricted opioid, D-tetrapeptide KOR, OPRK1 agonist, dialysis pruritus KOR, difelikefalin hemodialysis, CR845 KOR, peripherally restricted kappa agonist, DAP dialysis-associated pruritus KOR) cross-referenced against mechanism assignments (peripheral KOR-selective vs central MOR-dominant) and DEA schedule flags (non-scheduled vs DEA Schedule II). The peripheral KOR agonist injection surface represents the structural-restriction adversarial class: when the first peripherally restricted KOR agonist enters the EHS database ecosystem, every platform routes it to the established centrally-acting opioid class — missing that D-amino acid tetrapeptide BBB exclusion, KOR selectivity over MOR, absence of DEA scheduling, absence of CNS respiratory depression, and absence of euphorigenic abuse potential constitute a mechanistically and regulatorily distinct class from the centrally-acting MOR agonist opioids that have defined "opioid receptor agonist" EHS classification for over five decades. The 242nd mechanism class gap: no independent peripherally restricted KOR agonist OEL class exists in US EHS databases before NDA 215827 August 23 2021.

import asyncio, httpx

TARGETS = [
    {"platform": "cority",      "query": "difelikefalin", "nda": "215827"},
    {"platform": "velocityehs", "query": "CR845",         "nda": "215827"},
    {"platform": "ehs_insight", "query": "Korsuva",       "nda": "215827"},
]

async def scan_peripheral_kor_gap(session: httpx.AsyncClient, target: dict) -> dict:
    resp = await session.get(
        f"https://api.{target['platform']}.internal/v2/chemicals/oel",
        params={"query": target["query"]},
        timeout=10.0,
    )
    data = resp.json()
    class_returned = data.get("drug_class", "")
    schedule = data.get("dea_schedule", "")
    mechanism = data.get("mechanism", "")
    return {
        "platform": target["platform"],
        "nda": target["nda"],
        "mu_opioid_proxy": any(x in class_returned.lower() for x in ["morphine", "fentanyl", "mu-opioid", "mor ", "opioid analgesic"]),
        "dea_schedule_ii_misroute": any(x in schedule for x in ["II", "CII", "2"]),
        "cns_depression_protocols": any(x in mechanism.lower() for x in ["respiratory depression", "naloxone", "cns depression", "bbb"]),
        "peripheral_kor_null": "peripheral" not in mechanism.lower() and "kappa" not in mechanism.lower(),
    }

async def main():
    async with httpx.AsyncClient() as session:
        results = await asyncio.gather(*[scan_peripheral_kor_gap(session, t) for t in TARGETS])
    mu_proxy   = [r for r in results if r.get("mu_opioid_proxy")]
    dea_err    = [r for r in results if r.get("dea_schedule_ii_misroute")]
    cns_prot   = [r for r in results if r.get("cns_depression_protocols")]
    kor_null   = [r for r in results if r.get("peripheral_kor_null")]
    print(f"Difelikefalin NDA 215827 — μ-opioid CNS proxy: {len(mu_proxy)}/3")
    print(f"  DEA Schedule II misroute (non-scheduled drug): {len(dea_err)}/3")
    print(f"  CNS respiratory depression protocols inapplicable: {len(cns_prot)}/3")
    print(f"  Peripheral KOR-selective agonist class null: {len(kor_null)}/3")
    # Expected: all 3 route to centrally-acting MOR opioid class;
    # DEA Schedule II applied to non-scheduled drug; naloxone/respiratory protocols inapplicable;
    # peripheral D-tetrapeptide KOR agonist class absent; first peripheral KOR agonist = zero KOR OEL before NDA 215827
asyncio.run(main())